You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Outcomes of Patients with Melioidosis Treated with Meropenem
|
|---|---|
| Published in |
Antimicrobial Agents and Chemotherapy, April 2004
|
| DOI | 10.1128/aac.48.5.1763-1765.2004 |
| Pubmed ID | |
| Authors |
Allen C. Cheng, Dale A. Fisher, Nicholas M. Anstey, Dianne P. Stephens, Susan P. Jacups, Bart J. Currie |
| Abstract |
Melioidosis, an infection due to Burkholderia pseudomallei, is endemic in southeast Asia and northern Australia. We reviewed our experience with meropenem in the treatment of severe melioidosis in 63 patients over a 6-year period. Outcomes were similar to those of ceftazidime-treated patients (n = 153) despite a deliberate selection bias to more-unwell patients receiving meropenem. The mortality among meropenem-treated patients was 19%. One patient had a possible drug fever associated with the use of meropenem. We conclude that meropenem (1 g or 25 mg/kg every 8 h intravenously for >/=14 days) is an alternative to ceftazidime and imipenem in the treatment of melioidosis. The use of meropenem may be associated with improved outcomes in patients with severe sepsis associated with melioidosis. |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Thailand | 1 | 1% |
| Unknown | 69 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 13% |
| Student > Master | 9 | 13% |
| Student > Bachelor | 9 | 13% |
| Student > Ph. D. Student | 7 | 10% |
| Researcher | 6 | 8% |
| Other | 10 | 14% |
| Unknown | 21 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 32% |
| Agricultural and Biological Sciences | 7 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Immunology and Microbiology | 3 | 4% |
| Other | 5 | 7% |
| Unknown | 22 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2019.
All research outputs
#8,543,833
of 25,394,764 outputs
Outputs from Antimicrobial Agents and Chemotherapy
#7,471
of 15,582 outputs
Outputs of similar age
#20,926
of 62,213 outputs
Outputs of similar age from Antimicrobial Agents and Chemotherapy
#32
of 92 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 15,582 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 62,213 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 92 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.